Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

U.S. Economy Sends Mixed Signals, While Global Outlook Raises Concerns

The IMF's reduced global growth forecast, slower growth in China and Brexit uncertainty are among the negatives.

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

It has been a better year for the Russell 2000 and the small-caps it represents.

Small Caps Should Outperform in 2019

Small cap stocks should see much faster earnings growth than larger concerns.

They Aren't Sexy, but Solid Dividend-Paying Stocks Are a Portfolio Must

Chatham Lodging Trust and Cedar Fair are two well-run companies with very attractive yields that can help balance a portfolio.

Some Early 2019 Market Observations

I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.

2 Small-Caps That Should Continue to Stage Comebacks in 2019

Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

The Market in 2019: The Best of Times, The Worst of Times?

Stocks look very reasonably valued to start the new year.

2 Promising Biotech Stocks That Insiders Are Snapping Up

Shares of Iovance Biotherapeutics and Reata Pharmaceuticals took it on the chin in the fourth quarter, but both companies seem ready to reward shareholders for their patience.

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight